Therapeutic Response to Ramucirumab + Folfiri in Patients with Metastatic Gastric Cancer

Overview

Journal J Family Med Prim Care

Specialty Public Health

Date 2022 Dec 12

PMID 36505597

Authors

Hamid Rezvani

Shirin Haghighi

Mehdi Ghobakhlou

Elnaz Ataei

Affiliations

Soon will be listed here.

Abstract

Background: Gastric tumors are important gastrointestinal malignancies, and the prediction of therapeutic responses and related factors are important to improve the prognosis. Hence the aim of this study was to determine the therapeutic response to ramucirumab + folfiri in patients with metastatic gastric cancer.

Methods And Materials: In this prospective cohort, 13 consecutive patients with metastatic gastric cancer attending Taleghani Hospital that underwent ramucirumab + folfiri therapy were enrolled, and the therapeutic response among them was determined.

Results: The results in this study demonstrated that initial therapeutic response was 92.3% and the Progression-free Survival (PFS) was 16.2 months (84.6%) (CI95%:13.2-19.3). The nine-month PFS was 69.2%. Total survival was 16.7 months (CI95%:13.5-19.9).

Conclusion: Ultimately, according to the obtained results, it may be concluded that the therapeutic response to ramucirumab + folfiri in a patient with metastatic gastric cancer is good, and the use of this regimen is recommended.

References

Fuchs C, Muro K, Tomasek J, Van Cutsem E, Cho J, Oh S . Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data. J Gastric Cancer. 2017; 17(2):132-144. PMC: 5489542. DOI: 10.5230/jgc.2017.17.e16. View

Vogl U, Vormittag L, Winkler T, Kafka A, Weiser-Jasch O, Heinrich B . Ramucirumab plus paclitaxel or FOLFIRI in platinum-refractory advanced or metastatic gastric or gastroesophageal junction adenocarcinoma-experience at two centres. J Gastrointest Oncol. 2020; 11(2):366-375. PMC: 7212104. DOI: 10.21037/jgo.2020.03.10. View

Farhood B, Geraily G, Alizadeh A . Incidence and Mortality of Various Cancers in Iran and Compare to Other Countries: A Review Article. Iran J Public Health. 2018; 47(3):309-316. PMC: 5971166. View

Greig S, Keating G . Ramucirumab: A Review in Advanced Gastric Cancer. BioDrugs. 2015; 29(5):341-51. DOI: 10.1007/s40259-015-0138-1. View

Casak S, Fashoyin-Aje I, Lemery S, Zhang L, Jin R, Li H . FDA Approval Summary: Ramucirumab for Gastric Cancer. Clin Cancer Res. 2015; 21(15):3372-6. DOI: 10.1158/1078-0432.CCR-15-0600. View

Fala L . Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non-Small-Cell Lung Cancer. Am Health Drug Benefits. 2015; 8(Spec Feature):49-53. PMC: 4665044. View

Butler T, Maravent S, Boisselle J, Valdes J, Fellner C . A review of 2014 cancer drug approvals, with a look at 2015 and beyond. P T. 2015; 40(3):191-205. PMC: 4357352. View

de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D . Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012; 13(6):607-15. DOI: 10.1016/S1470-2045(12)70137-7. View

Roder D . The epidemiology of gastric cancer. Gastric Cancer. 2003; 5 Suppl 1:5-11. DOI: 10.1007/s10120-002-0203-6. View

10.

Moore M, Gill S, Asmis T, Berry S, Burkes R, Zbuk K . Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy. Ann Oncol. 2016; 27(12):2216-2224. DOI: 10.1093/annonc/mdw412. View

11.

Chen M, Lu S, Chen C, Lin P, Jiang J, Dyachkova Y . How May Ramucirumab Help Improve Treatment Outcome for Patients with Gastrointestinal Cancers?. Cancers (Basel). 2021; 13(14). PMC: 8306041. DOI: 10.3390/cancers13143536. View

12.

Winawer S . Gastric cancer: Worldwide burden and prevention opportunities. Chin J Dig Dis. 2005; 6(3):107-9. DOI: 10.1111/j.1443-9573.2005.00211.x. View

13.

Tabernero J, Yoshino T, Lee Cohn A, Obermannova R, Bodoky G, Garcia-Carbonero R . Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised,.... Lancet Oncol. 2015; 16(5):499-508. DOI: 10.1016/S1470-2045(15)70127-0. View

14.

Al-Batran S, Van Cutsem E, Oh S, Bodoky G, Shimada Y, Hironaka S . Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Ann Oncol. 2016; 27(4):673-9. PMC: 4803452. DOI: 10.1093/annonc/mdv625. View

15.

Javle M, Smyth E, Chau I . Ramucirumab: successfully targeting angiogenesis in gastric cancer. Clin Cancer Res. 2014; 20(23):5875-81. PMC: 4252869. DOI: 10.1158/1078-0432.CCR-14-1071. View

16.

Ahmadzadeh A, Seyedian S, Valizadeh A, Soleimani M, Nazari P, Hamidi H . The Efficacy and Safety of Modified Docetaxel, Cisplatin, and 5-Fluorouracil Vs. Epirubicin, Oxaliplatin, and Capecitabine Regimen in the Advanced Gastric Cancer: A Randomized Controlled Clinical Trial. Asian Pac J Cancer Prev. 2020; 21(3):727-732. PMC: 7437336. DOI: 10.31557/APJCP.2020.21.3.727. View